Halo.Jk
HALO.JK operates in the healthcare services and equipment industry, providing medical equipment, supplies, and distribution services.
Business. HALO.O is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on product sales within the Pharmaceuticals industry. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment breakdowns.
Analyst recommendations
9 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
- Congressional trades
- CongressJosh Gottheimer — Halozyme Therapeutics, Inc.2024-09-09 · Democrat · NJ · Sale · $1,001 - $15,000
- CongressJosh Gottheimer — Halozyme Therapeutics, Inc.2022-12-06 · Democrat · NJ · Sale · $1,001 - $15,000
- CongressJosh Gottheimer — Halozyme Therapeutics, Inc.2022-08-05 · Democrat · NJ · Sale · $1,001 - $15,000
Pre-earnings brief
Halozyme Therapeutics Inc (HALO.O) has recorded a major modification in its holder profile, marking the first analysis for this ticker. The most material change detected is a significant adjustment in the shareholding position of investor ID 929, as reported on June 20, 2026. This event represents a substantial shift in ownership structure, transitioning from a negligible weight to a more notable stake within the company’s top 35 holders. The specific data indicates that investor ID 929 increased their position from 610,000 shares to 983,842 shares as of March 31, 2026. This accumulation resulted in a dramatic rise in the value of the holding, which adjusted from approximately $0.79 million to $63.59 million. Consequently, the investor’s weight in the portfolio surged from 0.00014% to 1.17%, signaling a decisive increase in confidence or strategic allocation by this specific entity. This change is particularly significant given the current analyst coverage and corporate structure of Halozyme. With only three analysts covering the stock and no index membership, shifts in major holder positions can have a disproportionate impact on market perception and liquidity. The company, led by a single officer, now has a more concentrated institutional interest, which may influence future trading dynamics and price stability. The absence of prior basis for delta computation in this first analysis underscores the importance of establishing a new baseline for Halozyme’s shareholder composition. While no cross-source signals or additional material changes were detected, the magnitude of this single holder’s adjustment provides a critical data point for understanding the evolving interest in the biotechnology firm. Investors should monitor whether this accumulation reflects broader institutional trends or remains an isolated strategic move.
Signals & dispatch
Composite-score breakdown
Synthesis
HALO.O is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on product sales within the Pharmaceuticals industry. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment breakdowns.
The company maintains a strong liquidity position, with a current ratio of 3.88 and cash and equivalents amounting to 29,962,043,500 IDR. The liquidity FPT score indicates a low risk of liquidity distress, supported by a healthy cash reserve and minimal long-term debt exposure.
Profitability metrics show a return on equity (ROE) of 5.02% and a return on assets (ROA) of 3.6%, which are in line with the industry's preferred metrics. The company's gross profit margin is 16.67%, and its operating margin is 6.99%, both of which are consistent with the median for the medical equipment and supplies industry.
HALO.JK's revenue is primarily concentrated in the domestic market, with no significant international exposure disclosed. The company's business is segmented into medical equipment, supplies, and distribution, with no specific revenue breakdown provided. The lack of international diversification may pose a concentration risk, but the company's strong domestic presence mitigates this to some extent.
Looking ahead, the company is projected to maintain a stable growth trajectory, with no significant changes in revenue expected in the next fiscal year. Historical revenue growth has been steady, and the company's free cash flow of 14,871,132,400 IDR supports its ability to fund operations and potential expansion.
The risk assessment indicates a low probability of dilution and no immediate filing-based liquidity or dilution flags. The company's capital structure is conservative, with a debt-to-equity ratio of 0.0, and no long-term debt exposure. The absence of dilution risk is further supported by the company's strong equity position and low leverage.
Recent filings and transcripts do not indicate any material events that would significantly impact the company's operations or financial health. The company's financial statements show consistent performance, with no unusual items or accounting adjustments that would raise concerns.
Halozyme Therapeutics Inc (HALO.O) has recorded a major modification in its holder profile, marking the first analysis for this ticker. The most material change detected is a significant adjustment in the shareholding position of investor ID 929, as reported on June 20, 2026. This event represents a substantial shift in ownership structure, transitioning from a negligible weight to a more notable stake within the company’s top 35 holders. The specific data indicates that investor ID 929 increased their position from 610,000 shares to 983,842 shares as of March 31, 2026. This accumulation resulted in a dramatic rise in the value of the holding, which adjusted from approximately $0.79 million to $63.59 million. Consequently, the investor’s weight in the portfolio surged from 0.00014% to 1.17%, signaling a decisive increase in confidence or strategic allocation by this specific entity. This change is particularly significant given the current analyst coverage and corporate structure of Halozyme. With only three analysts covering the stock and no index membership, shifts in major holder positions can have a disproportionate impact on market perception and liquidity. The company, led by a single officer, now has a more concentrated institutional interest, which may influence future trading dynamics and price stability. The absence of prior basis for delta computation in this first analysis underscores the importance of establishing a new baseline for Halozyme’s shareholder composition. While no cross-source signals or additional material changes were detected, the magnitude of this single holder’s adjustment provides a critical data point for understanding the evolving interest in the biotechnology firm. Investors should monitor whether this accumulation reflects broader institutional trends or remains an isolated strategic move.
- HALO.JK maintains a strong liquidity position with a current ratio of 3.88 and significant cash reserves.
- The company's profitability metrics, including ROE and ROA, are in line with industry standards.
- HALO.JK's business is primarily concentrated in the domestic market, with no significant international exposure.
- The company is projected to maintain a stable growth trajectory with no significant changes in revenue expected.
- The risk assessment indicates a low probability of dilution and no immediate liquidity or dilution flags.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- SVP, CHIEF LEGAL OFFICER · Restricted Stock Units → Common StockDisposed 5 034exercise · 2026-06-12
- Director, PRESIDENT AND CEO · Option to Purchase Common Stock → Common StockDisposed 10 000 @ $12,07exercise · 2026-06-03
- Director, PRESIDENT AND CEO · Option to Purchase Common Stock → Common StockDisposed 20 000 @ $12,07exercise · 2026-06-02
- Director, PRESIDENT AND CEO · Option to Purchase Common Stock → Common StockDisposed 20 000 @ $12,07exercise · 2026-06-01
- Director, PRESIDENT AND CEO · Option to Purchase Common Stock → Common StockDisposed 10 000 @ $12,07exercise · 2026-05-13
- Director, PRESIDENT AND CEO · Option to Purchase Common Stock → Common StockDisposed 20 000 @ $12,07exercise · 2026-05-12
- Director, PRESIDENT AND CEO · Option to Purchase Common Stock → Common StockDisposed 20 000 @ $12,07exercise · 2026-05-11
- Director · Option to Purchase Common Stock → Common StockAcquired 6 040 @ $65,87grant · 2026-05-05
- Director · Option to Purchase Common Stock → Common StockAcquired 6 040 @ $65,87grant · 2026-05-05
- Director · Option to Purchase Common Stock → Common StockAcquired 6 040 @ $65,87grant · 2026-05-05
- Director · Option to Purchase Common Stock → Common StockAcquired 6 040 @ $65,87grant · 2026-05-05
- Director · Option to Purchase Common Stock → Common StockAcquired 6 040 @ $65,87grant · 2026-05-05
- Director · Option to Purchase Common Stock → Common StockAcquired 6 040 @ $65,87grant · 2026-05-05
- Director, PRESIDENT AND CEO · Option to Purchase Common Stock → Common StockDisposed 10 000 @ $12,07exercise · 2026-04-06
- Director, PRESIDENT AND CEO · Option to Purchase Common Stock → Common StockDisposed 20 000 @ $12,07exercise · 2026-04-02
- Director, PRESIDENT AND CEO · Option to Purchase Common Stock → Common StockDisposed 20 000 @ $12,07exercise · 2026-04-01
- Interim CFO · Restricted Stock Units → Common StockAcquired 10 000grant · 2026-04-01
- SVP, CHIEF OPERATING OFFICER · Option to Purchase Common Stock → Common StockDisposed 1 546 @ $33,51exercise · 2026-03-10
- SVP, CHIEF OPERATING OFFICER · Option to Purchase Common Stock → Common StockDisposed 20 000 @ $33,51exercise · 2026-03-09
- Director, PRESIDENT AND CEO · Option to Purchase Common Stock → Common StockDisposed 10 000 @ $12,07exercise · 2026-03-04
- Director, PRESIDENT AND CEO · Option to Purchase Common Stock → Common StockDisposed 20 000 @ $12,07exercise · 2026-03-03
- Director, PRESIDENT AND CEO · Option to Purchase Common Stock → Common StockDisposed 20 000 @ $12,07exercise · 2026-03-02
- SVP, CHIEF FINANCIAL OFFICER · Performance Stock Units → Common StockDisposed 6 688exercise · 2026-02-23
- Director, PRESIDENT AND CEO · Restricted Stock Units → Common StockDisposed 22 436exercise · 2026-02-23
- SVP, CHIEF LEGAL OFFICER · Restricted Stock Units → Common StockDisposed 7 011exercise · 2026-02-23
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- HALO.JK Market data — financials · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,07 %$96M
- Investment Managers · as of 2026-03-310,07 %$124M
- Institutional Investor · as of 2026-03-310,04 %$80M
- Investment Managers · as of 2026-03-310,04 %$117M
- Investment Managers · as of 2026-03-310,03 %$65M
- Investment Managers · as of 2026-03-310,03 %$134M
- Investment Managers · as of 2024-12-310,02 %$73M
- Investment Managers · as of 2026-03-310,01 %$23M
- Investment Managers · as of 2026-03-310,01 %$83M
- Institutional Investor · as of 2026-03-310,01 %$64M
- Investment Managers · as of 2025-12-310,01 %$778M
- Investment Managers · as of 2026-03-310,01 %$162M
- Investment Managers · as of 2026-03-310,01 %$29M
- Investment Managers · as of 2026-03-310,01 %$72M
- Investment Managers · as of 2026-03-310,01 %$17M
- Institutional Investor · as of 2022-09-300,01 %$0M
- Investment Managers · as of 2026-03-310,01 %$13M
- Investment Managers · as of 2026-03-310,01 %$47M
- Investment Managers · as of 2026-03-310,00 %$13M
- Investment Managers · as of 2026-03-310,00 %$11M
- Institutional Investor · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$8M
- Funds · as of 2026-03-310,00 %$8M
- Investment Managers · as of 2024-06-300,00 %$39M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$12M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$3M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$1M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Helen I TorleyPresident, Chief Executive Officer, Director
Insider activity
- SVP, CHIEF LEGAL OFFICER · Common StockOther 2 715 @ $69,50$189K · 2026-06-12
- SVP, CHIEF LEGAL OFFICER · Common StockOther 5 034 · 2026-06-12
- Director, PRESIDENT AND CEO · Common StockSold 1 500 @ $67,67$102K · 2026-06-03
- Director, PRESIDENT AND CEO · Common StockSold 6 100 @ $69,69$425K · 2026-06-03
- Director, PRESIDENT AND CEO · Common StockOther 10 000 @ $12,07$121K · 2026-06-03
- Director, PRESIDENT AND CEO · Common StockSold 400 @ $66,37$27K · 2026-06-03
- Director, PRESIDENT AND CEO · Common StockSold 2 000 @ $68,74$137K · 2026-06-03
- Director, PRESIDENT AND CEO · Common StockSold 16 600 @ $66,31$1,1M · 2026-06-02
- Director, PRESIDENT AND CEO · Common StockSold 3 400 @ $66,75$227K · 2026-06-02
- Director, PRESIDENT AND CEO · Common StockOther 20 000 @ $12,07$241K · 2026-06-02
- Director · Common StockSold 1 625 @ $66,21$108K · 2026-06-01
- Director, PRESIDENT AND CEO · Common StockSold 1 610 @ $66,39$107K · 2026-06-01
- Director, PRESIDENT AND CEO · Common StockSold 12 989 @ $67,41$876K · 2026-06-01
- Director, PRESIDENT AND CEO · Common StockSold 5 401 @ $68,35$369K · 2026-06-01
- Director, PRESIDENT AND CEO · Common StockOther 20 000 @ $12,07$241K · 2026-06-01
- Director, PRESIDENT AND CEO · Common StockSold 600 @ $70,81$42K · 2026-05-13
- Director, PRESIDENT AND CEO · Common StockOther 10 000 @ $12,07$121K · 2026-05-13
- Director, PRESIDENT AND CEO · Common StockSold 2 100 @ $68,10$143K · 2026-05-13
- Director, PRESIDENT AND CEO · Common StockSold 3 350 @ $68,88$231K · 2026-05-13
- Director, PRESIDENT AND CEO · Common StockSold 3 950 @ $69,79$276K · 2026-05-13
- Director, PRESIDENT AND CEO · Common StockOther 20 000 @ $12,07$241K · 2026-05-12
- Director, PRESIDENT AND CEO · Common StockSold 100 @ $67,85$7K · 2026-05-12
- Director, PRESIDENT AND CEO · Common StockSold 1 398 @ $70,29$98K · 2026-05-12
- Director, PRESIDENT AND CEO · Common StockSold 9 802 @ $71,37$700K · 2026-05-12
- Director, PRESIDENT AND CEO · Common StockSold 5 900 @ $72,15$426K · 2026-05-12
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Debt-to-equity (FY 2025-12-31): 50.73xDerived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 37.6%Derived (calculated)
- Current ratio (FY 2025-12-31): 4.66xDerived (calculated)
- Return on assets (FY 2025-12-31): 12.5%Derived (calculated)
- Net margin (FY 2025-12-31): 22.7%Derived (calculated)
- Return on equity (FY 2025-12-31): 649.2%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 36.0%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 22.4%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -15.0%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -28.6%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -86.6%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 42.3%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -25.4%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 45.7%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -24.6%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 43.5%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 15.5%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -34.8%Derived (calculated)
- Net income (annual): USD 316.89MSEC XBRL filing
- Shares outstanding (annual): 117.78MSEC XBRL filing
- Current liabilities (annual): USD 177.09MSEC XBRL filing
- Capex (annual): USD 6.97MSEC XBRL filing
- Current assets (annual): USD 825.21MSEC XBRL filing
- Cash & equivalents (annual): USD 133.82MSEC XBRL filing